<DOC>
	<DOCNO>NCT00630565</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy colony-stimulating factor , G-CSF , may increase number stem cell blood . The stem cell collect patient 's blood store . Chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . PURPOSE : This clinical trial study well autologous stem cell transplant work treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Stem Cell Transplant Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - To assess whether sufficient peripheral blood stem cell ( PBSC ) collect patient acute myeloid leukemia ( AML ) use cyclophosphamide , etoposide , granulocyte-colony stimulating factor ( G-CSF ) mobilization . - To assess rate myeloid , platelet , erythroid recovery follow autologous PBSC transplant . - To assess disease-free survival rate patient AML receive PBSC auto graft . OUTLINE : - Chemotherapy filgrastim ( G-CSF ) prim PBSC collection : Patients receive cyclophosphamide IV day 0 ; etoposide IV 3 hour day 0 1 ; oral dexamethasone twice daily day 0 1 . Patients also receive G-CSF subcutaneously ( SC ) begin day 3 continue apheresis complete . After blood count recover , apheresis perform 4-6 daily plan collection minimum CD34+ cell dose &gt; 2.5 x 10^6 cells/kg achieve . If minimum CD34+ cell dose achieve 6 apheresis collection , patient undergo bone marrow examination include bone marrow biopsy aspiration , termination PBSC collection confirm remission . If remission confirm , peripheral count marrow cellularity sufficient , patient remain G-CSF 7 day receive sargramostim ( GM-CSF ) 5 day increase marrow cellularity , bone marrow harvest perform . - Bone marrow harvest without prior PBSC collection : Children undergo prim bone marrow harvest comprise GM-CSF IV SC 5 day prior harvest increase cellularity marrow harvest . Marrow blood specimen also obtain initial bone marrow evaluation time harvest cytogenetic abnormality previously describe . Other patient unable undergo PBSC collection may proceed bone harvest discretion protocol chairperson . - Cytoreductive regimen : - Patients 2 year old : Patients undergo total body irradiation ( TBI ) twice daily day -7 -4 ( total 8 fraction ) , cyclophosphamide IV 2 hour day -3 -2 , follow 1-day rest period day -1 . - Patients 2 year old patient undergo TBI : Patients receive busulfan IV orally every 6 hour day -7 -4 , cyclophosphamide IV 2 hour day -3 -2 , follow 1-day rest period day -1 . - Stem cell transplantation : All patient undergo autologous PBSC and/or bone marrow infusion day 0 . Patients also receive G-CSF IV SC begin day 1 continue blood count recover . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Children age two eligible protocol , receive total body irradiation . Instead , child age two receive Busulfan/Cyclophosphamide ( Bu/Cy ) condition preparative regimen order obviate deleterious effect radiation age . Patients receive total body irradiation ( TBI ) ( example prior radiation therapy ) also receive Bu/CY conditioning . Acute myeloid leukemia ( AML ) All child adult less age 70 AML achieve first second bone marrow remission eligible protocol . Patients must undergo peripheral blood stem cell collection marrow harvest remission must expect well outcomes allogeneic transplantation . Patients cytogenetic abnormality suggest improved prognosis [ ( 8:21 ) , ( 15 ; 17 ) inv ( 16 ) ] eligible transplantation first remission . Allogeneic transplant HLAidentical sibling recommend patient &lt; 55 year . If patient refuse allogeneic transplant , may still eligible protocol . Patients also deem eligible transplant specific organ toxicity . Specifically , patient preexist compromise heart , lung , kidney , CNS liver may exclude : Eastern Cooperative Oncology Group ( ECOG ) Performance status : 0 1 Heart The patient must free symptom uncontrolled cardiac disease , must compromise cardiac function detect ECHO gate cardiac blood flow scan ( MUGA ) LVEF &gt; 45 % ) . Kidney The patient must correct creatinine clearance &gt; 50 % normal . Liver The total serum bilirubin &lt; 2.5 mg/dL ; ALT &lt; 2 x upper limit normal . Lung Patients must significant obstructive airway disease rest hypoxemia ( PO2 &lt; 80 ) , must acceptable diffusion capacity ( DLCO &gt; 50 % predict ) . Central Nervous System ( CNS ) : Patients must free active ongoing ischemic degenerative CNS disease active resistant CNS leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
</DOC>